Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Кожные реакции на кардиологические препараты: клинический случай
Кожные реакции на кардиологические препараты: клинический случай
Невозинская З.А., Пирузян А.Л., Корсунская И.М. Кожные реакции на кардиологические препараты: клинический случай. Consilium Medicum. 2020; 22 (10): 80–82. DOI: 10.26442/20751753.2020.10.200267
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Фотодерматиты, вызванные применением лекарственных препаратов, являются важной и актуальной проблемой в практике врачей. Это связано с тем, что вызывать развитие фотодерматитов может целый ряд широко используемых в медицине лекарственных средств – антибиотики и сульфаниламиды, нестероидные противовоспалительные препараты, противоопухолевые препараты, диуретики, гипотензивные и антиаритмические препараты, антидиабетические и психиатрические средства, третиноин и изотретиноин, а также некоторые другие. Фотодерматиты, вызванные применением лекарственных средств, протекают по типу фототоксических реакций. Лекарственные вещества в данной ситуации в коже могут играть роль фотосенсибилизатора. Патомеханизм развития фототоксических реакций основан на накоплении в коже вещества, которое обладает свойствами фотосенсибилизатора, и одновременного воздействия на кожу солнечного излучения. Фотосенсибилизатор, повышая чувствительность кожи к видимой или ультрафиолетовой части спектра, приводит к развитию высыпаний. В своей статье мы описали случай 64-летнего пациента, у которого развился фотодерматит на фоне длительного приема амиодарона.
Ключевые слова: фотодерматит, фототоксические реакции, амиодарон.
Key words: photodermatitis, phototoxic reactions, amiodarone.
Ключевые слова: фотодерматит, фототоксические реакции, амиодарон.
________________________________________________
Key words: photodermatitis, phototoxic reactions, amiodarone.
Полный текст
Список литературы
1. Wilm A, Berneburg M. Photoallergy. J Dtsch Dermatol Ges 2015; 13: 7–12.
2. Bylaite M, Grigaitiene J, Lapinskaite GS. Photodermatoses: classification, evaluation and management. Br J Dermatol 2009; 161 (Suppl. 3): 61–8.
3. Honari G. Photoallergy. Rev Environ Health. 2014; 29: 233–42.
4. Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007; 6: 431–43.
5. Ladizinski B, Elpern DJ. Dronaderone-induced phototoxicity. J Drugs Dermatol 2013; 12 (8): 946–7.
6. Maoz KB, Dvash S, Brenner S, Brenner S. Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas. Int J Dermatol 2009; 48 (12): 1398–400. DOI: 10.1111/j.1365-4632.2008.03819.x
7. Lankerani L, Baron ED. Photosensitivity to exogenous agents. J Cutan Med Surg 2004; 8 (6): 424–31.
8. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf 2011; 34 (10): 821–37. DOI: 10.2165/11592780-000000000-00000
9. Jaworski K, Walecka I, Rudnicka L et al. Cutaneous adverse reactions of amiodarone. Med Sci Monit 2014; 20: 2369–72. DOI: 10.12659/MSM.890881
10. Bongard V, Marc D, Philippe V et al. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther 2006; 13 (4): 315–9.
11. Ammoury A, Michaud S, Paul C et al. Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. Arch Dermatol 2008; 144 (1): 92–6. DOI: 10.1001/archdermatol.2007.25
12. Yones SS, O'Donoghue NB, Palmer RA et al. Persistent severe amiodarone-induced photosensitivity. Clin Exp Dermatol 2005; 30 (5): 500–2.
13. Shah N, Warnakulasuriya S. Amiodarone-induced peri-oral photosensitivity. J Oral Pathol Med 2004; 33 (1): 56–8.
14. Rappersberger K, Honigsmann H, Ortel B et al. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol 1989; 93: 201–9.
15. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298 (11): 1312–22.
16. Ferguson J, Addo HA, Jones S et al. A study of cutanous photosensitivity induced by amiodarone. Br J Dermatol 1985; 113: 537–49.
17. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2 (4): 253–62.
2. Bylaite M, Grigaitiene J, Lapinskaite GS. Photodermatoses: classification, evaluation and management. Br J Dermatol 2009; 161 (Suppl. 3): 61–8.
3. Honari G. Photoallergy. Rev Environ Health. 2014; 29: 233–42.
4. Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007; 6: 431–43.
5. Ladizinski B, Elpern DJ. Dronaderone-induced phototoxicity. J Drugs Dermatol 2013; 12 (8): 946–7.
6. Maoz KB, Dvash S, Brenner S, Brenner S. Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas. Int J Dermatol 2009; 48 (12): 1398–400. DOI: 10.1111/j.1365-4632.2008.03819.x
7. Lankerani L, Baron ED. Photosensitivity to exogenous agents. J Cutan Med Surg 2004; 8 (6): 424–31.
8. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf 2011; 34 (10): 821–37. DOI: 10.2165/11592780-000000000-00000
9. Jaworski K, Walecka I, Rudnicka L et al. Cutaneous adverse reactions of amiodarone. Med Sci Monit 2014; 20: 2369–72. DOI: 10.12659/MSM.890881
10. Bongard V, Marc D, Philippe V et al. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther 2006; 13 (4): 315–9.
11. Ammoury A, Michaud S, Paul C et al. Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. Arch Dermatol 2008; 144 (1): 92–6. DOI: 10.1001/archdermatol.2007.25
12. Yones SS, O'Donoghue NB, Palmer RA et al. Persistent severe amiodarone-induced photosensitivity. Clin Exp Dermatol 2005; 30 (5): 500–2.
13. Shah N, Warnakulasuriya S. Amiodarone-induced peri-oral photosensitivity. J Oral Pathol Med 2004; 33 (1): 56–8.
14. Rappersberger K, Honigsmann H, Ortel B et al. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol 1989; 93: 201–9.
15. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298 (11): 1312–22.
16. Ferguson J, Addo HA, Jones S et al. A study of cutanous photosensitivity induced by amiodarone. Br J Dermatol 1985; 113: 537–49.
17. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2 (4): 253–62.
2. Bylaite M, Grigaitiene J, Lapinskaite GS. Photodermatoses: classification, evaluation and management. Br J Dermatol 2009; 161 (Suppl. 3): 61–8.
3. Honari G. Photoallergy. Rev Environ Health. 2014; 29: 233–42.
4. Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007; 6: 431–43.
5. Ladizinski B, Elpern DJ. Dronaderone-induced phototoxicity. J Drugs Dermatol 2013; 12 (8): 946–7.
6. Maoz KB, Dvash S, Brenner S, Brenner S. Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas. Int J Dermatol 2009; 48 (12): 1398–400. DOI: 10.1111/j.1365-4632.2008.03819.x
7. Lankerani L, Baron ED. Photosensitivity to exogenous agents. J Cutan Med Surg 2004; 8 (6): 424–31.
8. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf 2011; 34 (10): 821–37. DOI: 10.2165/11592780-000000000-00000
9. Jaworski K, Walecka I, Rudnicka L et al. Cutaneous adverse reactions of amiodarone. Med Sci Monit 2014; 20: 2369–72. DOI: 10.12659/MSM.890881
10. Bongard V, Marc D, Philippe V et al. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther 2006; 13 (4): 315–9.
11. Ammoury A, Michaud S, Paul C et al. Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. Arch Dermatol 2008; 144 (1): 92–6. DOI: 10.1001/archdermatol.2007.25
12. Yones SS, O'Donoghue NB, Palmer RA et al. Persistent severe amiodarone-induced photosensitivity. Clin Exp Dermatol 2005; 30 (5): 500–2.
13. Shah N, Warnakulasuriya S. Amiodarone-induced peri-oral photosensitivity. J Oral Pathol Med 2004; 33 (1): 56–8.
14. Rappersberger K, Honigsmann H, Ortel B et al. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol 1989; 93: 201–9.
15. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298 (11): 1312–22.
16. Ferguson J, Addo HA, Jones S et al. A study of cutanous photosensitivity induced by amiodarone. Br J Dermatol 1985; 113: 537–49.
17. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2 (4): 253–62.
________________________________________________
2. Bylaite M, Grigaitiene J, Lapinskaite GS. Photodermatoses: classification, evaluation and management. Br J Dermatol 2009; 161 (Suppl. 3): 61–8.
3. Honari G. Photoallergy. Rev Environ Health. 2014; 29: 233–42.
4. Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007; 6: 431–43.
5. Ladizinski B, Elpern DJ. Dronaderone-induced phototoxicity. J Drugs Dermatol 2013; 12 (8): 946–7.
6. Maoz KB, Dvash S, Brenner S, Brenner S. Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas. Int J Dermatol 2009; 48 (12): 1398–400. DOI: 10.1111/j.1365-4632.2008.03819.x
7. Lankerani L, Baron ED. Photosensitivity to exogenous agents. J Cutan Med Surg 2004; 8 (6): 424–31.
8. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf 2011; 34 (10): 821–37. DOI: 10.2165/11592780-000000000-00000
9. Jaworski K, Walecka I, Rudnicka L et al. Cutaneous adverse reactions of amiodarone. Med Sci Monit 2014; 20: 2369–72. DOI: 10.12659/MSM.890881
10. Bongard V, Marc D, Philippe V et al. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther 2006; 13 (4): 315–9.
11. Ammoury A, Michaud S, Paul C et al. Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. Arch Dermatol 2008; 144 (1): 92–6. DOI: 10.1001/archdermatol.2007.25
12. Yones SS, O'Donoghue NB, Palmer RA et al. Persistent severe amiodarone-induced photosensitivity. Clin Exp Dermatol 2005; 30 (5): 500–2.
13. Shah N, Warnakulasuriya S. Amiodarone-induced peri-oral photosensitivity. J Oral Pathol Med 2004; 33 (1): 56–8.
14. Rappersberger K, Honigsmann H, Ortel B et al. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol 1989; 93: 201–9.
15. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298 (11): 1312–22.
16. Ferguson J, Addo HA, Jones S et al. A study of cutanous photosensitivity induced by amiodarone. Br J Dermatol 1985; 113: 537–49.
17. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2 (4): 253–62.
Авторы
З.А. Невозинская1,2, А.Л. Пирузян3, И.М. Корсунская*3
1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ГБУЗ «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. Москвы, Москва, Россия;
3 ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, Москва, Россия
*marykor@bk.ru
1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology, Moscow, Russia;
3 Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
*marykor@bk.ru
1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ГБУЗ «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. Москвы, Москва, Россия;
3 ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, Москва, Россия
*marykor@bk.ru
________________________________________________
1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology, Moscow, Russia;
3 Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
*marykor@bk.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.